Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013–2020
Dermatitis® · 2023
DOI: 10.1089/derm.2022.29013.ewa ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, 2023. Verfasst von Erin M Warshaw und 17 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Sunscreening Agents, Dermatitis, Allergic Contact. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Benzophenone (BZP)-3 and BZP-4 are ultraviolet (UV) absorbers used in sunscreens and personal care products (PCPs) and may cause allergic contact dermatitis.
Objective
To characterize positive patch test reactions to BZP-3 (10% in petrolatum [pet]) and BZP-4 (2% pet) in a screening allergen series.
Methods
Retrospective analysis of patients tested to BZP-3 and BZP-4 was conducted by the North American Contact Dermatitis Group from 2013 to 2020.
Results
Of 19,618 patients patch tested to BZP-3 and BZP-4, 103 (0.5%) and 323 (1.6%) had positive reactions, respectively: 413 (2.1%) reacted to at least 1 BZP (BZP-positive patient). As compared with BZP-negative patients, BZP-positive patients were significantly more likely to have a history of hay fever (39.3% vs 33.4%, P = 0.0134), history of atopic dermatitis (39.8% vs 30.7%, P = 0.0001), and facial involvement (37.4% vs 32.2%, P = 0.0272). Most reactions were currently clinically relevant (BZP-3: 90.4%; BZP-4: 65.8%). Common identified sources included PCPs and sunscreens. Coreactivity between BZP-3 and BZP-4 was low: 13.5% (14/104) of BZP-3-positive patients were allergic to BZP-4 and 4.3% (14/322) of BZP-4-positive patients were allergic to BZP-3.
Conclusions
Eight-year prevalence of BZP positivity was 2.1%. Reactions were frequently clinically relevant and linked to PCPs and sunscreens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.
- Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.
- Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- Department of Dermatology, Columbia University Irving Medical School, New York, New York, USA.
- Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Zitieren
APA
Warshaw, E. M., Xiong, M., Belsito, D. V., Adler, B. L., Atwater, A. R., DeKoven, J. G., Taylor, J. S., Reeder, M. J., Houle, M. C., Silverberg, J. I., Pratt, M. D., Dunnick, C. A., Botto, N., DeLeo, V. A., Mowad, C. M., Maibach, H. I., Yu, J., & Fowler, J. F. (2023). Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013–2020. Dermatitis®. https://doi.org/10.1089/derm.2022.29013.ewa
Vancouver
Warshaw EM, Xiong M, Belsito DV, Adler BL, Atwater AR, DeKoven JG, et al. Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013–2020. Dermatitis®. 2023. doi:10.1089/derm.2022.29013.ewa
BibTeX
@article{Warshaw2023,
author = {Warshaw, Erin M and Xiong, Michelle and Belsito, Donald V and Adler, Brandon L and Atwater, Amber R and DeKoven, Joel G and Taylor, James S and Reeder, Margo J and Houle, Marie-Claude and Silverberg, Jonathan I and Pratt, Melanie D and Dunnick, Cory A and Botto, Nina and DeLeo, Vincent A and Mowad, Christen M and Maibach, Howard I and Yu, JiaDe and Fowler, Joseph F},
title = {Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013–2020},
journal = {Dermatitis®},
year = {2023},
doi = {10.1089/derm.2022.29013.ewa}
}
EUVIMED